These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 19432114)

  • 1. [Alendronate for treatment of osteoporoses].
    Harada A
    Nihon Rinsho; 2009 May; 67(5):943-7. PubMed ID: 19432114
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [New development in bisphosphonate treatment. When and how long should patients take bisphosphonates for osteoporosis?].
    Yamaguchi T; Sugimoto T
    Clin Calcium; 2009 Jan; 19(1):38-43. PubMed ID: 19122263
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bisphosphonates and low-impact femoral fractures: current evidence on alendronate-fracture risk.
    Schneider JP
    Geriatrics; 2009 Jan; 64(1):18-23. PubMed ID: 19256578
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Efficacy and tolerability of once-weekly administration of 35 mg alendronate and 17.5 mg risedronate].
    Kishimoto H
    Nihon Rinsho; 2007 Nov; 65 Suppl 9():365-8. PubMed ID: 18161133
    [No Abstract]   [Full Text] [Related]  

  • 5. [Diphosphonate therapy and osteonecrosis of the jaw].
    Løkken P; Skoglund LA; Skjelbred P
    Tidsskr Nor Laegeforen; 2007 Aug; 127(15):1945-7. PubMed ID: 17700737
    [No Abstract]   [Full Text] [Related]  

  • 6. Atypical femoral fractures shortly after osteonecrosis of the jaw in a postmenopausal woman taking alendronate for osteoporosis.
    Chiu WY; Lee JJ; Tsai KS
    J Clin Endocrinol Metab; 2013 Apr; 98(4):E723-6. PubMed ID: 23471975
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bisphosphonate-induced osteonecrosis of the jaw.
    Sharma V; Nagaraj S; Choksey U; Hegde A; Samant R; Balakrishnan C
    J Assoc Physicians India; 2011 Aug; 59():516-7. PubMed ID: 21887911
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Evidence and utility of etidronate for the treatment of osteoporosis].
    Takada J; Iba K; Yamashita T; Yoshizaki T
    Clin Calcium; 2008 Oct; 18(10):1427-33. PubMed ID: 18830039
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Are there any alternatives to alendronate (Fosamax) for osteoporosis to avoid the risk of osteonecrosis of the jaw?
    Wynn RL
    Gen Dent; 2007; 55(6):495-8. PubMed ID: 18050572
    [No Abstract]   [Full Text] [Related]  

  • 10. [New development in bisphosphonate treatment. Bisphosphonates for the treatment of glucocorticoid-induced osteoporosis].
    Soen S
    Clin Calcium; 2009 Jan; 19(1):44-53. PubMed ID: 19122264
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Study finds no link between bone drugs and unusual thigh fractures.
    Harv Womens Health Watch; 2010 Jul; 17(11):6. PubMed ID: 20684079
    [No Abstract]   [Full Text] [Related]  

  • 12. [Measurement of bone mineral density is necessary for monitoring of bisphosphonate treatment].
    Soen S
    Clin Calcium; 2011 Jan; 21(1):116-9. PubMed ID: 21187604
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Retrospective study of two biochemical markers for the risk assessment of oral bisphosphonate-related osteonecrosis of the jaws: can they be utilized as risk markers?
    Kwon YD; Ohe JY; Kim DY; Chung DJ; Park YD
    Clin Oral Implants Res; 2011 Jan; 22(1):100-5. PubMed ID: 20946206
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [New development in bisphosphonate treatment. Fracture prevention by bisphosphonates].
    Hosoi T
    Clin Calcium; 2009 Jan; 19(1):11-8. PubMed ID: 19122260
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fosamax and osteonecrosis of the jaw--important questions and answers.
    Wynn RL
    Gen Dent; 2008; 56(4):315-7. PubMed ID: 19284187
    [No Abstract]   [Full Text] [Related]  

  • 16. [Osteoporotic fracture in menopausal women: alendronate reduces the risk].
    Bize R; Lamy O; Peytremann-Bridevaux I
    Rev Med Suisse; 2008 Dec; 4(183):2703. PubMed ID: 19157286
    [No Abstract]   [Full Text] [Related]  

  • 17. [Drug therapy for prevention of falls and fractures].
    Ringe JD
    Med Klin (Munich); 2006 Jun; 101 Suppl 1():1-5. PubMed ID: 16826362
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A review of the literature on osteonecrosis of the jaw in patients with osteoporosis treated with oral bisphosphonates: prevalence, risk factors, and clinical characteristics.
    Pazianas M; Miller P; Blumentals WA; Bernal M; Kothawala P
    Clin Ther; 2007 Aug; 29(8):1548-58. PubMed ID: 17919538
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nonexposed variant of bisphosphonate-associated osteonecrosis of the jaw: a case series.
    Fedele S; Porter SR; D'Aiuto F; Aljohani S; Vescovi P; Manfredi M; Arduino PG; Broccoletti R; Musciotto A; Di Fede O; Lazarovici TS; Campisi G; Yarom N
    Am J Med; 2010 Nov; 123(11):1060-4. PubMed ID: 20851366
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Reliably combined to combat osteoporosis].
    MMW Fortschr Med; 2005 Dec; 147(51-52):63. PubMed ID: 16402714
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.